Drugs / Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05020860 Comparator | Apr 2023 → Aug 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma +1 | Baylor Breast Care Center | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pertuzumab/Trastuzumab/Hyaluronidase-zzxf | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05020860 ↗ |